SPARC and neoplasm: Recently, a mannosylated albumin delivery platform able to target both SPARC and CD206 was proposed in order to provide a more efficient way to target drug-resistant cancer cells and reprogram tumor-associated macrophages that over-express the mannose receptor [67].